

MISSION-1

Join the **Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment-1 Study!**

People with Down syndrome often have immune systems that don't work quite like the immune systems of people without Down syndrome. This can cause more inflammation and health problems. The MISSION-1 study aims to see if tofacitinib (or XELJANZ®) can help reduce these problems and improve health in people with Down syndrome.



WHAT DOES THE STUDY INVOLVE?

TREATMENT

Some participants will get tofacitinib for six months. Others will get a placebo for six months. Participants will not know if they are getting the medicine or not. People who get the placebo will have the option to get tofacitinib for an additional six months.

DURATION

Both groups will take an oral liquid twice daily for six months. Participants in the placebo arm will have the option to take tofacitinib for an additional six months, bringing the total study duration to 12 months.

REQUIREMENTS

Participants will attend research visits at the University of Colorado Anschutz, in Denver, CO over the course of six to 12 months.

Compensation is provided and travel reimbursement may be available



WHO CAN JOIN?

- People ages 6 to 22 with Down syndrome
- Weigh at least 22 pounds
- Have a caregiver who can help with study tasks
- Individuals cannot join if they have recently taken certain medicines, have certain health conditions or have undergone specific medical treatments.

INTERESTED?



SCAN THE QR CODE

Questions?
Contact the research team at dsresearch@cuanschutz.edu



LINDA CRNIC INSTITUTE
for DOWN SYNDROME

PI: **Joaquin Espinosa**
COMIRB# 24-0432



IS THE MEDICINE SAFE?

The medicine has been used safely for other conditions, like arthritis, in both adults and children. In earlier studies, people with Down syndrome who used tofacitinib had good results with few side effects. This study will carefully monitor each participant for any side effects, making sure it's safe.